Navigation Links
Resverlogix's Success in Inflammation Program Results in 2 Patents Filed
Date:5/19/2009

grow to US $27 billion by the year 2015. These important markets require novel therapies to reduce pain and symptoms in a cost efficient manner. Resverlogix's novel small molecules have the illustrated early potential to fill this important gap.

Kenneth Lebioda, Senior Vice President of Business & Corporate Development of Resverlogix stated, "The inflammation market is enormous with many significant unmet needs. Current leading therapeutics such as biologics are effective, but also very expensive. Resverlogix's platform technology has created novel small molecules which illustrate potent anti-inflammatory effects in arthritis models as compared with leading biologic agents." Lebioda highlighted, "The early efficacy data from these compounds is exciting for the reason that small molecules would offer significant cost savings to health systems over current biologic agents."

Inflammation is a normal response of the body to protect tissues from infection, injury or disease. Though it promotes healing, if uncontrolled, the inflammatory response may become harmful. Acute or chronic inflammation is known to play a key role in diverse disease states, such as atherosclerosis and rheumatoid arthritis. Worldwide it is estimated that more than 80 million people suffer from inflammatory diseases.

Resverlogix will be presenting at the BIO Business Forum held at the Convention Center in Atlanta, Georgia on Wednesday, May 20, 2009 at 9:20 am EDT in Room 313.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
2. Kendle Announces Departure of Senior Vice President and CFO Karl Buzz Brenkert III; Appoints Keith A. Cheesman as Successor
3. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
8. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
9. Addiction Treatment Finds Success Treating Brain Deficiencies through the Belly
10. Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
11. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Oct. 21 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... nationwide and internationally, is pleased to announce that Chairman, CEO ... Operations, will appear for one hour live on "Go Rogue ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... financial results on Wednesday, October 27, 2010, after the market ... call at 5:00 p.m. ET, which will be open to ... the company will review the financial results and discuss other ...
... and NEW YORK, Oct. 20 ACCESS ... ACCP ), a biopharmaceutical company leveraging its proprietary drug-delivery ... supportive care and diabetes, announced it has submitted additional ... formulations of many global top-100 injectable drugs, as a ...
Cached Biology Technology:Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network 2Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
(Date:7/9/2014)... an economy driven by methane, the primary component of natural ... production boom. It has poised the country as a top ... over just how climate-friendly it is, according to an article ... news magazine of the American Chemical Society. , In the ... when burned as a fuel to produce electricity, methane emits ...
(Date:7/9/2014)... at the NIH,s National Center for Advancing ... treat sickle cell disease has been acquired ... candidate, Aes-103, is the first specifically developed ... sickle cell disease. Baxter now will advance ... approval and commercialization. , Sickle cell disease ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... 5, 2008 Scientists report online this week in ... of specialized gut immune cells to a gene associated ... inflammatory bowel disorder. The link to immune cells ... St. Louis because they and others believe Crohn,s disease ...
... found the key to engineering plants capable of thriving ... report published online on October 2nd in Current ... that is generally plentiful in the earth,s crustcauses particular ... where acidic environments turn the metal into a form ...
... the power of 21st century computing to confirm an idea ... cycles evolve faster. Their findings appear in the October 3rd ... consequence for the understanding of evolution made possible by the ... said senior author Michael Donoghue , the G. Evelyn ...
Cached Biology News:Form of Crohn's disease traced to disabled gut cells 2How to build crops that can beat aluminum's toxic effects 2Reproducing early and often is the key to rapid evolution in plants 2
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: